BG
BLCM

Bellevue Group’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Bellevue Group’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-9,002
Closed -$664K – 144
2018
Q2 		$664K Buy
+9,002
New +$702K 0.06% 129

Other funds holding BLCM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bellevue Group's BLCM Position: Q3 2018 in Review

Bellevue Group sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2018, closing a stake of 9,002 shares — an estimated $664K sold.

Bellevue Group first reported a position in BLCM in Q2 2018 and held it in 1 quarter. The position peaked at $664K in Q2 2018. 100 funds tracked by Wall St. Rank hold BLCM as of Q3 2018.

  • Bellevue Group reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Bellevue Group sold 9,002 Bellicum Pharmaceuticals, Inc. shares in Q3 2018, an estimated $664K.
  • Bellevue Group first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2018 and held it in 1 quarter.
  • Bellevue Group's Bellicum Pharmaceuticals, Inc. position peaked at $664K in Q2 2018.
  • 100 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2018.

Based on Bellevue Group's 13F filing for Q3 2018, filed 13 Nov 2018.